Analyst Ratings February 6, 2026

Wolfe Research Lowers Crown Holdings Rating as Valuation Catch-Up Limits Upside

Analyst trims rating to Peerperform after rally; JPMorgan also pares stance despite a slightly higher price target

By Derek Hwang CCK
Wolfe Research Lowers Crown Holdings Rating as Valuation Catch-Up Limits Upside
CCK

Wolfe Research downgraded Crown Holdings (CCK) from Outperform to Peerperform, citing a narrowing valuation gap with peers after a strong share-price run. The packaging company has shown sustained fundamental progress, including deleveraging and robust cash generation, but recent multiple compression reduces near-term upside. Crown reported Q4 2025 adjusted EPS that beat estimates, yet investor concerns about growth and market conditions weighed on premarket trading. JPMorgan also moved its rating to Neutral while raising its price target modestly.

Key Points

  • Wolfe Research cut Crown Holdings to Peerperform after a strong share-price rally and narrowing valuation spread versus peers.
  • The company has improved fundamentals, targeting roughly 2.5x net leverage in 2025, with a financial health score of 3.27 and a Piotroski Score of 8; management has also pursued buybacks, yielding about 9% free cash flow.
  • Crown beat Q4 2025 adjusted EPS estimates ($1.74 vs $1.70) but shares slipped in premarket trading amid concerns about future growth; JPMorgan downgraded to Neutral while raising its price target to $115.00.

Wolfe Research on Friday lowered its recommendation on Crown Holdings (NYSE: CCK), moving the stock from Outperform to Peerperform. The decision reflects the research firm's view that the stock's rally has left a more balanced risk/reward profile, reducing potential near-term upside.

Crown has posted a notable 32.15% total return over the past year and is trading near its 52-week high of $115.85. Wolfe Research acknowledged the company's consistent operational and financial improvements over the past two-plus years, but concluded that the narrowing valuation spread versus peers has limited how much further the stock can run in the near term.

Financial progress and capital returns

Management has focused on deleveraging and capital allocation. The company expects net leverage to fall to roughly 2.5x in 2025 as part of a broader effort to strengthen its balance sheet. InvestingPro data cited in the firm's analysis shows a financial health score of 3.27, categorized as "GREAT," and a Piotroski Score of 8, underlining improved fundamentals.

Wolfe Research also noted Crown's moves to reconfigure its asset base to a more efficient footprint across beverage can and transit packaging operations, and the firm highlighted an active share-buyback program. InvestingPro data attributes a roughly 9% free cash flow yield to Crown, a level that has supported buybacks and contributed to shareholder returns.

Valuation view and peer comparison

While Wolfe Research did not describe the stock's valuation as excessively high, it pointed out that the discount to peers has compressed over the past two years. That compression, according to the research house, translates into reduced upside potential from current levels. The downgrade to Peerperform reflects this more constrained upside rather than a conclusion that Crown's valuation is rich in absolute terms.

Earnings and market reaction

In other developments, Crown reported adjusted earnings per share of $1.74 for the fourth quarter of 2025, topping analysts' consensus of $1.70. Despite the beat, the stock fell in premarket trading as some investors weighed concerns about future growth and broader market conditions.

JPMorgan recently adjusted its view as well, downgrading Crown from Overweight to Neutral and citing valuation concerns as a driver. At the same time, JPMorgan raised its price target on the stock from $112.00 to $115.00, signaling some upward revision to its view of the company's price potential even amid a more cautious rating.

Bottom line

The sequence of analyst moves and the company's strong recent performance underscore a shift from undervaluation toward parity with peers. That shift has prompted at least two major firms to temper their recommendations, leaving Crown in a position where continued fundamental progress may be necessary to deliver further share-price appreciation.


Key points

  • Wolfe Research downgraded Crown from Outperform to Peerperform after a strong stock rally and narrowing valuation spread versus peers.
  • Crown's fundamentals have improved, with expected net leverage near 2.5x in 2025, a high financial health score, and a Piotroski Score of 8; management has also prioritized buybacks and generated about a 9% free cash flow yield.
  • Q4 2025 adjusted EPS of $1.74 beat the $1.70 analyst estimate, but the shares fell in premarket trading amid investor concerns about growth and market conditions; JPMorgan also downgraded to Neutral while raising its price target to $115.00.

Risks and uncertainties

  • Narrowing valuation gap with peers reduces near-term upside potential for the stock - this affects equity investors and portfolio managers focused on packaging and materials sectors.
  • Investor concerns about future growth and broader market conditions may continue to pressure the stock despite strong recent earnings - this impacts market sentiment in consumer packaging and related supply chains.
  • Analyst downgrades driven by valuation worries can influence trading dynamics and cost of capital perceptions for the company - relevant to corporate finance and capital allocation decisions within the packaging industry.

Risks

  • Valuation compression versus peers reduces near-term upside potential for the stock, affecting investors in the packaging and materials sectors.
  • Ongoing investor concerns about future growth and market conditions could weigh on share performance despite recent earnings beats.
  • Analyst downgrades linked to valuation concerns may influence market sentiment and capital allocation choices within the packaging industry.

More from Analyst Ratings

Stifel Lowers JFrog Target Citing AI-Driven Security Concerns; Maintains Buy Rating Feb 22, 2026 HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026